Marshall Wace
DYN icon

Marshall Wace’s Dyne Therapeutics DYN Stock Holding History

Marshall Wace’s Portfolio DYN Stock Details DYN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$33.1M Buy
1,488,917
+1,405,770
+1,691% +$26.1M 0.03% 522
2026
Q1 		$1.51M Sell
83,147
-593,832
-88% -$10.2M ﹤0.01% 1935
2025
Q4 		$13.2M Sell
676,979
-2,336,398
-78% -$44.2M 0.01% 769
2025
Q3 		$38.1M Buy
3,013,377
+2,565,570
+573% +$29.3M 0.04% 409
2025
Q2 		$4.26M Buy
+447,807
New +$4.93M ﹤0.01% 1222
2025
Q1 		– Sell
-24,501
Closed -$577K – 2727
2024
Q4 		$577K Buy
+24,501
New +$725K ﹤0.01% 1982
2024
Q3 		– Sell
-273,567
Closed -$9.65M – 2602
2024
Q2 		$9.65M Buy
273,567
+219,862
+409% +$6.39M 0.01% 743
2024
Q1 		$1.52M Buy
+53,705
New +$1.21M ﹤0.01% 1482
2023
Q4 		– Sell
-22,052
Closed -$198K – 2271
2023
Q3 		$198K Hold
22,052
– – ﹤0.01% 1976
2023
Q2 		$248K Sell
22,052
-110,292
-83% -$1.3M ﹤0.01% 2189
2023
Q1 		$1.52M Buy
132,344
+110,292
+500% +$1.43M ﹤0.01% 1609
2022
Q4 		$256K Sell
22,052
-42,858
-66% -$496K ﹤0.01% 2618
2022
Q3 		$824K Sell
64,910
-284,369
-81% -$3.26M ﹤0.01% 2497
2022
Q2 		$2.4M Hold
349,279
– – ﹤0.01% 1870
2022
Q1 		$3.37M Hold
349,279
– – 0.01% 1711
2021
Q4 		$4.15M Buy
349,279
+327,227
+1,484% +$4.6M 0.01% 1503
2021
Q3 		$358K Hold
22,052
– – ﹤0.01% 2568
2021
Q2 		$464K Buy
+22,052
New +$415K ﹤0.01% 2168

Other funds holding DYN

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $881M AUM 160.77% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Marshall Wace's DYN Position: Q2 2026 in Review

Marshall Wace increased its Dyne Therapeutics (DYN) stake by 1,691% in Q2 2026, buying an estimated $26.1M and bringing the position to 1,488,917 shares worth $33.1M. The position accounts for 0.03% of the portfolio, ranked #522.

Marshall Wace first reported a position in DYN in Q2 2021 and has held it in 18 quarters since. The position peaked at $38.1M in Q3 2025. 245 funds tracked by Wall St. Rank hold DYN as of Q2 2026.

  • Marshall Wace held 1,488,917 shares of Dyne Therapeutics worth $33.1M as of Q2 2026.
  • Marshall Wace bought 1,405,770 Dyne Therapeutics shares in Q2 2026, an estimated $26.1M.
  • Dyne Therapeutics made up 0.03% of Marshall Wace's portfolio in Q2 2026, its #522 holding.
  • Marshall Wace first reported a position in Dyne Therapeutics in Q2 2021 and has held it in 18 quarters since.
  • Marshall Wace's Dyne Therapeutics position peaked at $38.1M in Q3 2025.
  • 245 funds tracked by Wall St. Rank held Dyne Therapeutics as of Q2 2026.

Based on Marshall Wace's 13F filing for Q2 2026, filed 13 Aug 2026.